메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Chiron Medical Launches "Early Check, Early Hope" Campaig…

HONG KONG, Oct. 13, 2025 -- According to government statistics[1], breast cancer ranks as the third leading cause of cancer deaths among women in Hong Kong, with an average of one in every 14 women likely to be diagnosed with the disease in their lifetime. The medical community widely believes that early detection significantly increases the success rate of treatment, making regular screenings and disease awareness essential. In celebration of Pink Day and International Breast Cancer Awareness Month, Chiron Medical invites all sectors to participate in launching "Early Check, Early Hope,
- 김갑성 기자
- 2025-10-13 19:46
LTS expands its CDMO capabilities with the acquisition of Re…

ANDERNACH, Germany, Oct. 13, 2025 -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company today announces the acquisition of Renaissance Lakewood, LLC ("Renaissance"), a US-based contract development and manufacturing organization (CDMO) specializing in nasal sprays and sterile dosage forms. With the acquisition, Renaissance facilities will become part of the worldwide operations network of LTS, along with LTS' existing facilities in Andernach, Germany, West Caldwell, NJ, US, St. Paul, MN, US and Netanya, Israel. The acquisitio
- 김갑성 기자
- 2025-10-13 18:00
ReviR Therapeutics Receives Orphan Drug Designation from…

BRISBANE, Calif. , Oct. 13, 2025 -- ReviR Therapeutics, a biotech company focused on developing novel treatments for neurogenetic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for RTX-117, its lead investigational therapy for Charcot-Marie-Tooth disease (CMT). ReviR is preparing to launch a Phase 1 clinical trial in healthy volunteers in early 2026 to evaluate the safety, tolerability, and pharmacokinetics of RTX-117, with a Phase Ib/IIa study in CMT patients planned to follow. CMT is the most prevalent inherited p
- 김갑성 기자
- 2025-10-13 18:00
AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025

TAIPEI, Oct. 13, 2025 -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the World Muscle Society (WMS) 2025 International Congress in Vienna. Dr. Tahseen Mozaffar, an investigator of the study, presented the study outcome, emphasizing the therapeutic potential of AJ201 for SBMA patients. AJ201, an oral suspension of a novel curcumin analog-Rosolutamide, offers ease of use for patients with s
- 김갑성 기자
- 2025-10-13 16:03
The 138th Canton Fair is Set to Open in Guangzhou on Octob…

GUANGZHOU, China, Oct. 13, 2025 -- The 138th China Import and Export Fair (Canton Fair) is set to open in Guangzhou from October 15 to November 4, divided into three phases. The fair will maintain its 24-hour online presence to offer global buyers continuous access to Chinese suppliers. With an exhibition area of 1.55 million square meters, this session will feature a record 74,600 booths and more than 32,000 participating enterprises. The 138th Canton Fair marks a new milestone in both scale and innovation. For the first time, more than 10,000 exhibitors hold titles such as &q
- 김갑성 기자
- 2025-10-13 14:42
Lundbeck's bexicaserin receives Breakthrough Therapy D…

[ 메디채널 김갑성 기자 ] Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies Novel 5HT2C mechanism designed to reduce drug-resistant seizures in children and adults living with Developmental Epileptic Encephalopathies (DEEs) and improve quality of life for patients and their caregivers1 Dual Breakthrough Therapy Designation (BTD) in China and the U.S. underscores Lundbeck's mission to advance brain health and transform lives of patients with rare neurological diseases VALBY, Denmark, Oct. 13, 2025 -- Lundbeck tod
- 김갑성 기자
- 2025-10-13 14:26
ISTH marks World Thrombosis Day with urgent global call to ac…

[ 메디채널 김갑성 기자 ] Thrombosis is the underlying cause of 1 in 4 deaths worldwide each year. The campaign calls for crucial awareness and prevention. CHARLOTTE, N.C., Oct. 13, 2025 -- The International Society on Thrombosis and Haemostasis (ISTH) today marks World Thrombosis Day, a global movement uniting thousands of partners in more than 120 countries. This year's campaign, "From Head to Toe, Take Control. Prevent Thrombosis. Protect Your Health," calls for greater awareness of thrombosis and action to reduce its burden worldwide. Observed annually on October
- 김갑성 기자
- 2025-10-13 14:00
Singclean Anti-adhesion Technology With Professor Osam…

CAPE TOWN, South Africa, Oct. 13, 2025 -- Singclean Medical, in partnership with Kayan Al-Seha Medical (KSM) and Professor Osama Shawki, successfully made its debut at the FIGO World Congress of Gynecology and Obstetrics 2025, held from October 5–9 at the Cape Town International Convention Centre. Participation at FIGO, marks a key milestone in Singclean's global strategy and growing influence in women's healthcare. Singclean Innovative Anti-adhesion Technology with Professor Osama Shawki at Figo 2025 Professor Osama Shawki's Keynote Highlights Singclean® Adhesio
- 김갑성 기자
- 2025-10-13 13:00
GC Biopharma Secures CMO Rights for Shingles Vaccine from…

YONGIN, South Korea, Oct. 13, 2025 -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development. Under the terms of the agreement, GC Biopharma will be responsible for producing a portion of the commercial supply of amezosvatein for global markets. The global shingles vaccine market is currently dominated by GSK's Shingrix.
- 김갑성 기자
- 2025-10-13 12:38
Smartee Launches World's First Sleep Aligner Combining Ant…

SHANGHAI, Oct. 13, 2025 -- Smartee Denti-Technology today announced the global launch of the Smartee Sleep Aligners, a clear aligner device designed to help manage obstructive sleep apnoea hypopnoea syndrome (OSAHS) and primary snoring (PS). The new series includes two versions: Smartee SA, which focuses on the treatment of OSAHS and PS, and Smartee SA Plus. The latter can treat OSAHS while simultaneously addressing orthodontic issues. Together, they provide clinicians with an invisible alternative to conventional OSAHS treatment therapies, offering greater comfort and compliance, and improvi
- 김갑성 기자
- 2025-10-13 09:38

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분